BAHA Osseointegrated denied as non-formulary by Cigna?

Cigna's specific coverage criteria for baha osseointegrated are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denies BAHA (Bone-Anchored Hearing Aid) as Non-Formulary

Although BAHA is a surgically implanted device rather than a pharmacy product, Cigna structures coverage of implantable auditory devices through a benefit-tier framework analogous to a drug formulary. A non-formulary denial means the specific BAHA model or brand submitted for authorization is not on Cigna's approved-device list, or that the device-coverage benefit is excluded from the member's specific plan unless an exception is granted. Patients on employer-sponsored plans with limited device benefits most frequently encounter this denial type.

## Why This Denial Is Appealable

Non-formulary status for a medical device does not end the coverage inquiry. Most Cigna plans offer a coverage-exception pathway when: (1) no formulary-covered alternative exists that addresses the same clinical need, or (2) the covered alternative is clinically inappropriate for the specific patient. The appeal must document both the clinical necessity of BAHA for this patient and why any covered alternative is inadequate. Benefit-design challenges (plan exclusion) require a different approach — a written explanation of why the exclusion violates applicable mental-health parity, rehabilitation, or habilitation benefit requirements, if applicable.

## Your Federal Appeal Rights

• Internal appeal: ACA §2719 and ERISA §503 provide full-and-fair internal review rights. The denial must specify the benefit-tier or formulary provision applied.
• External review: Available after a final internal denial. The external-review window is generally approximately four months. IROs can review whether a non-formulary determination was correctly applied under plan terms.
• Expedited review: Request if delay is causing ongoing significant communication-function impairment.

## Documentation to Gather

1. Audiological evaluation — current audiogram and word-recognition scores documenting hearing-loss type and severity. 2. Device-selection rationale — a signed letter from the implanting surgeon or audiologist explaining why this specific BAHA model was chosen, including any anatomic, audiologic, or patient-specific factors that make it the appropriate choice. 3. Covered-alternative comparison — if Cigna's formulary lists an alternative device, a clinical explanation of why that device does not address this patient's specific need (different indication, anatomic incompatibility, prior failed trial). 4. FDA-clearance documentation — clearance summary confirming the requested device is FDA-cleared for this patient's hearing-loss indication. 5. Formal exception request — a written formulary- or device-exception request invoking Cigna's exception process, submitted concurrently with or prior to the appeal.

## Criteria-Mapping Structure

Obtain Cigna's device-exception policy and the relevant benefit-coverage policy for BAHA. Identify each criterion for granting a non-formulary exception. Map each criterion to a specific supporting document. Present the mapping as a structured table. If the denial is a plan-level benefit exclusion rather than a formulary-tier issue, consult with a patient advocate or benefits attorney about whether applicable federal parity or habilitation-benefit requirements override the exclusion.